Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Osteoporosis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Osteoporosis
    Once-Yearly Zoledronic Acid Approved in EU for Glucocorticoid-Induced Osteoporosis - (DGNews)
    TopAbstracts in Osteoporosis 06/23/2009 - (DGNews)
    Study Defines Strategy to Protect Bones in Women, Girls With Primary Ovarian Insufficiency - (DGNews)
    Zoledronic Acid Increases Bone Mineral Density in Men After Recent Hip Fracture: Presented at ENDO 09 - (DGDispatch)
    Treatment With Zoledronic Acid Shows Early, Persistent Reduction in the Risk of Fracture in Women: Presented at ENDO 09 - (DGDispatch)

    News archive

     Recent webcasts/CME - Osteoporosis
    The Evaluation and Management of Osteoporosis Encountered in Children and Adults with Developmental Disabilities

    Webcasts/CME archive

     Recent cases - Osteoporosis
      A Productive Cough
      Operative Management of a Subtrochanteric Fracture in Severe Osteoporosis: A Case Report
      Bilateral Femoral Neck Fractures Due to Transient Osteoporosis of Pregnancy: A Case Report
      A Clay-Shoveler's Fracture with Renal Transplantation and Osteoporosis: A Case Report
      Stress Fracture of the Femoral Neck in a 24-Year-Old Female with Anorexia Nervosa Induced Osteoporosis

      Cases archive
        




      my personal edition > osteoporosis > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Weekly Risedronate as Good as Daily for Osteoporosis: Presented at WCO

      By Adrian Burton
      Special to DG News

      LISBON, PORTUGAL -- May 14, 2002 -- Once-weekly doses of risedronate 35 mg increase the bone mineral density (BMD) of the lumbar spine and hip of postmenopausal women as effectively as the standard 5 mg daily regimen, according to researchers.

      Weekly dosing could free many patients from the inconvenience of daily doses that must be taken on an empty stomach.

      "One of the major issues clinicians face today is how to help patients adhere to their therapy: how do we make it convenient enough for them," said Jonathon Adachi, MD, professor of medicine at McMaster University, Hamilton, Ontario, Canada.

      "Earlier studies have shown once-weekly dosing can be a more convenient treatment. We wanted to know the safety and efficacy of risedronate at different weekly doses," he said. Dr. Adachi presented the findings here Monday at the International Osteoporosis Foundation World Congress on Osteoporosis (WCO).

      The double-blind, randomised study was conducted in Canada and the United States and included 1,456 osteoporotic women aged 50 or older, all of whom were more than five years past menopause. For enrollment, women had to have a lumbar spine T-score of less than -2.5 or less than -2.0 and at least one important vertebral fracture.

      The researchers divided the women into three dosing groups: 480 received 5 mg risedronate daily; 485 received 35 mg once a week; and 491 received 50 mg once a week. The women in the weekly dosing groups took placebo tablets on non-dosing days.

      At 12 months, all dosing regimens provided similar increases in lumbar spine bone mineral density (BMD) over baseline levels (4.00 percent, 3.94 percent, and 4.25 percent, respectively). Total hip BMD, femoral neck BMD, and trochanteric BMD were also increased by similar amounts. Differences between the various dosing regimens were less than 0.5 percent.

      Reductions in bone turnover markers showed a similar trend. N-telopeptide /creatinine ratios were down from baseline by 60 percent, 61 percent, and 65 percent, respectively, and bone alkaline phosphatase levels were down 42 percent, 41 percent, and 46 percent, respectively.

      There were no differences in adverse effects -- including gastrointestinal problems -- between the three regimens. Once-weekly regimens therefore appear to be as effective as the once-daily standard, and because no extra benefit was seen with the 50 mg weekly dose, the most recommendable dose is 35 mg weekly, said Dr. Adachi.

      "The number one thing for the younger working person really does come down to convenience," he said. "You may have 8:00 appointments and you want breakfast, but you can't have any because you have to take your pill on a daily basis -- so maybe you don't take it. If you could take just one pill on the weekend, people could tolerate this much better."



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send